Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8741-8750 Newer>

Chemistry World January 7, 2014 Angeli Mehta	Flu drug stockpile may be worthless The case for spending hundreds of millions of pounds stockpiling antivirals for use in a flu pandemic is based on 'judgement rather than on evidence of their effectiveness', according to a parliamentary committee.
Chemistry World January 7, 2014 Derek Lowe	Is there a drug for that? One hears a lot about the concept of 'druggability' in pharmaceutical research. If that concept has any meaning (and it probably does), then the implication is that there must be such a thing as 'undruggability'. So what does that look like?
Chemistry World January 6, 2014 Sarah Houlton	Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed.
Chemistry World January 3, 2014 Ben Valsler	Sanofi suffers multiple sclerosis setback French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration rejected its multiple sclerosis drug Lemtrada (alemtuzumab).
Information Today January 2, 2014	Springer Journals Get New Creative Commons License Beginning Feb. 3, 2014, a Creative Commons Attribution 4.0 International license will apply to journals from BioMed Central, Chemistry Central, and SpringerOpen, which are all part of Springer Science+Business Media.
Chemistry World December 23, 2013 Jennifer Newton	AstraZeneca claims quashed in heartburn drug patent case An appeals court has ruled in favor of Hanmi Pharmaceuticals in a patent dispute over AstraZeneca's best-selling acid reflux drug Nexium (esomeprazole magnesium).
Chemistry World December 20, 2013 Patrick Walter	Chinese police seize 222m pounds of fake drugs Counterfeit medicines and raw materials worth more than Yuan2.2 billion have been seized by Chinese authorities.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
Chemistry World December 19, 2013 Steven Ford	Cut price pills cost more than pennies We need to take a good look at supply diversity: we cannot allow the situation where suppliers are too big to fail. It's time to raise the bar across the pharmaceutical supply line from producer to patient.
Information Today December 9, 2013 Marydee Ojala	Informa Acquires Elsevier Business Intelligence Depending upon how well Informa integrates EBI into its existing pharmaceutical research products, the addition of these publications creates interesting competitive pressures for Thomson Reuters' Cortellis platform and for Wolters Kluwer Health.
<Older 8741-8750 Newer> Return to current articles.